This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agnelli, G. Articles by Hirsh, J. Search for Related Content PubMed PubMed Citation Articles by Agnelli, G. Articles by Hirsh, J.

(Circulation. 1995;92:2819-2824.)
© 1995 American Heart Association, Inc.

Articles

Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins

Clinical Implications for the Treatment of Thromboembolic Diseases

Presented in part during the 66th Scientific Sessions of the American Heart Association, Atlanta, Ga, November 8-11, 1993.

Giancarlo Agnelli; Alfonso Iorio; Cinzia Renga; Enrico Boschetti; Giuseppe G. Nenci; Frederick A. Ofosu; Jack Hirsh

From the Istituto di Medicina Interna e di Medicina Vascolare, Università di Perugia, Italy; and the Hamilton Civic Hospital Research Centre, McMaster University, Hamilton, Ontario, Canada.

Correspondence to Giancarlo Agnelli, MD, Istituto di Medicina Interna e di Medicina Vascolare, Università di Perugia, via Enrico dal Pozzo, 06122 Perugia, Italy.

Background The mechanism for the efficacy of once- or twice-daily subcutaneous injections of low-molecular-weight heparins (LMWHs) for the treatment of venous thromboembolism has been difficult to explain. The confusion exists because the observation from experimental studies that the antithrombin activity of LMWHs is necessary for their antithrombotic effect is inconsistent with the reported short half-life of the antithrombin activity of LMWHs. Previous pharmacokinetic studies were performed with lower doses of LMWHs than have been used in contemporary trials, and antithrombin activity was assessed with the barely sensitive chromogenic assay.

Methods and Results We performed a pharmacokinetic study to compare the relative half-lives of prophylactic and therapeutic doses of LMWHs assessing antithrombin activity with both the chromogenic and a more sensitive assay (plasma thrombin neutralization assay). An eight-way cross-over randomized study in healthy volunteers was performed. Enoxaparin (20 and 40 mg and 1 and 2 mg/kg) and nadroparin (7500 and 10 000 ICU and 225 and 450 ICU/kg) were administered subcutaneously. The maximal peak activity for aPTT ratio was 1.7. A dose-dependent peak activity was found for both antifactor Xa and antithrombin activities. Disappearance time of these activities after the highest dose of both LMWHs was longer than 16 hours. Overall mean antifactor Xa activity half-life was 4.6 hours. Overall mean antithrombin activity half-life was longer than 4 hours.

Conclusions Our results provide an explanation for the effectiveness of LMWHs administered either once or twice daily. High and sustained plasma antithrombin activity is achieved when LMWHs are administered in therapeutic doses used in contemporary trials with only a moderate prolongation of the aPTT.

Key Words: low-molecular-weight heparins • thrombin • thromboembolic diseases

This article has been cited by other articles:

				J. M. Wilson, J. Gilbert, M. Harlan, A. Bracey, P. Allison, C. Schooley, and K. Pinto High-dose Intravenous Dalteparin Can be Monitored Effectively Using Standard Coagulation Times Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 127 - 138. [Abstract] [PDF]

				S. Z. Goldhaber, K. Dunn, M. Gerhard-Herman, J. K. Park, and P. M. Black Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis Chest, December 1, 2002; 122(6): 1933 - 1937. [Abstract] [Full Text] [PDF]

				S.Z. Goldhaber Modern treatment of pulmonary embolism Eur. Respir. J., February 1, 2002; 19(35_suppl): 22S - 27s. [Abstract] [Full Text] [PDF]

				C. Pechlaner, W. Gritsch, and C. Wiedermann Enoxaparin for acute coronary syndromes? J. Am. Coll. Cardiol., June 1, 2001; 37(7): 2007 - 2007. [Full Text] [PDF]

				G. G Nenci and A. Minciotti Low molecular weight heparins for arterial thrombosis Vascular Medicine, November 1, 2000; 5(4): 251 - 258. [Abstract] [PDF]

				Y. Tien, C. Yang, K. Ng, M. Wu, P. Lai, and C. Huang Thrombosis of the inferior vena cava in a pregnant woman with nephrotic syndrome - diagnostic and therapeutic dilemma Nephrol. Dial. Transplant., January 1, 1999; 14(1): 210 - 213. [Abstract] [PDF]

				J. Fareed, D. Hoppensteadt, W. Jeske, R. Clarizio, J. M. Walenga, and R. L. Bick The Available Low Molecular Weight Heparin Preparations Are Not the Same Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S38 - S52. [PDF]